A July 2021 market research report valued the gene therapy market at US$524 million in 2018 with a compound annual growth rate of 40.7% by 2025. This growing market is a hotbed of activity in numerous areas, and many new companies have sprung up to capture this market in the past year.
This Resolute Research Report highlights recent activity in gene therapy over the last year (July 1, 2020-July 1, 2021). All information and visualizations have been extracted from ResoluteAI’s Foundation platform.
In July 2021, there’s been a flurry of activity for gene therapy and genomic companies in the IPO world.
Immuneering, a Cambridge, Mass., preclinical biotechnology company that targets signaling pathways to treat cancer and neurological diseases, filed for an IPO on July 9. The company, founded in 2008, has received over $57 million in funding to date. Immuneering hopes to raise up to $100 million in its IPO and plans to list on the Nasdaq under the symbol IMRX.
Omega Therapeutics, a preclinical biotechnology company developing gene therapies for cancer and other diseases, also filed for an IPO on July 9. The Cambridge, Mass., company, which was founded in 2016, wants to raise up to $100 million in its IPO and plans to list on the Nasdaq under OMGA. As of March 2021, Omega has raised $211 million.
Tenaya Therapeutics, a South San Francisco, Calif., gene therapy developer focused on heart disease, also filed for an IPO on July 9 and hopes to raise up to $100 million. Founded in 2016, Tenaya has raised $248 million in total and plans to list on the Nasdaq under TNYA.
95 tech transfer opportunities
for gene therapy were made available for licensing in the last year.
In our analysis of 300+ university tech transfer sites: 25 licensing opportunities came from Stanford University who focused on CRISPR, adeno-associated virus, ribonucleotide reductase inhibitor , and aldehyde dehydrogenase.
Number of tech transfer opportunities and the associated research area
1443 academic grants were awarded
by government agencies to fund gene therapy research.
Upon review of grant award recipients documented in NIH, NSF, SBIR, Horizon 2020, and Wellcome: 59 grants were awarded to the University of California and 45 grants were awarded to the University of Washington.
Organizations and the grants they received by amount. Note - $0 represents grants less than $100,000
24,000 peer-reviewed publications
related to gene therapy were made publicly available.
China led the way with the most publications (6,694), and the U.S. wasn’t far behind with 5,015. Five countries accounted for 14,440 of these over 24,000 publications: China, the U.S., Italy, Germany, and Japan. The top author for China was Jin Wang with 36 publications, and for the U.S., it was Alex Philippidis.
This network graph shows the connections between authors and organizations
are working in the area of gene therapy.
academic institutions, we found the universities with the most researchers exploring gene therapy by research area. The University of California-San Francisco had the most researchers in areas related to gene therapy followed by Cornell University.
Top five institutions with the most researchers in gene therapy by research area
36,547 news articles published
within the last year related to gene therapy.
The top five companies mentioned in the news during this time period were: Novartis AG (3081), Pfizer Inc. (1854), Roche Holding AG (1500), Sanofi SA (1369). Bristol-Myers Squibb (932). Novartis AG had the most articles, and most of those concerned spinal muscular atrophy.
Top 20 companies most often mentioned in gene therapy news in the last year
The five universities mentioned most frequently in gene therapy news in the past year were: Stanford University (238), University of Oxford (210), University College London (187), Harvard Medical School (184), Columbia University (179). Stanford University had the most news articles, and the most common topic was repetitive DNA sequences.
Top 20 universities mentioned in gene therapy news in the last year
1265 gene therapy companies in Crunchbase
243 companies received funding in the last year.
The top five investors that provided funding of $100,000,000 or more towards companies developing products in gene therapy: ARCH Venture Partners, Atlas Venture, Casdin Capital, GV, OrbiMed.
Top five investors and the stages they invested in companies
1,084 clinical trials
involving gene therapy began within the last year.
MD Anderson Cancer Center currently is recruiting for the most clinical trials.
Top five facilities conducting gene therapy clinical trials and sponsor name, and the status of the trial
16,476 patents were submitted/granted
last year involving gene therapy.
The National Institutes of Health had the most patents granted during this period while the Regents of the University of California had the most applications.
Top five patent assignees for the period including filing status and publication date
Gene therapy– A new era of opportunity
The gene therapy market is expected to boom over the next decade based on the significant amount of activity in R&D and developers entering the space.
As FDA Commissioner Stephen Hahn said, “These [gene] therapies, once only conceptual, are rapidly becoming a therapeutic reality for an increasing number of patients with a wide range of diseases, including rare genetic disorders and autoimmune diseases.”
Gene therapy offers a new chance at treating rare medical cases and genetic disease, and the industry is recognizing the immense opportunity that has arrived with it.
Gene therapy companies that have received a funding total of $100,000,000 or more
Interested in seeing a specific landscape?